Company intelligence / Profile preview
ErVimmune
Lyon, Auvergne-Rhône-Alpes, Franceervimmune.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
As of early 2026, ErVimmune is transitioning into its first-in-human clinical phase following a €17 million Series A funding round. The lead program, ErVac01, is an off-the-shelf therapeutic cancer vaccine designed to target human endogenous retrovirus (HERV) antigens in patients with triple-negative breast cancer and ovarian cancer. The company aims to establish safety and immunogenicity in these initial clinical trials.
- Therapeutic areas
- OncologyHematology
- Modalities
- VaccineCell therapyT cell receptor engineered T cell therapyTherapeutic vaccineTCR-T cell therapyRecombinant vector vaccine
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Servier
Beyond the preview
Go deeper on ErVimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ErVimmune.